BioSpace News Archive

In a matter of days, every health center in America stands to lose more than 70% of their federal grant funding without Congress extending the funding by September 30.

Locations in Westborough, Watertown, and Cambridge

Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the 14-Day version of the Carnation Ambulatory Monitor (“CAM™"), the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

Danielle Geissler, Ph.D., senior principal, ALULA – Dr. Geissler is a multi-industry expert at applying the science of behavior to individual and organizational transformation.

SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treating hereditary retinal degenerative diseases such as retinitis pigmentosa, announced today that the company will be part of the leading industry showcase meeting to present a Company update.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management’s presentation at the H.C. Wainwright 21st Annual Global Investment Conference has been moved to 2:35 p.m. Eastern time on Tuesday, September 10.

Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memorandum of understanding for the creation of a significant multi-national Sumitomo Dainippon-Roivant Alliance (“Alliance”) that will include Roivant’s ownership interests in Urovant Sciences and four additional biopharmaceutical “Vant” companies.

Dr. Reddy’s Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) announced that the Company will be presenting at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, 2019, in New York City.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for building on the success of its biosimilar switching program and called on other provinces to implement similar programs.

Endo International plc (NASDAQ: ENDP) announced today that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.